Recent news from 24dunia
   

Search results for  

ptrsu result bcom iii 

 ( 1-10 )
Sort by: Relevance |   Date
 

18,000 examinees appear in CSJMU back paper exam

students of various courses appeared in back paper examinations conducted byCollege, Halim Muslim College, VSSD College Mahila Maha Vidyalaya, DG College, Kanpur Vidya Mandir, PPN College and AND College.Examinations of BA-I, BCom-I, BSc-I and MCom I and II were held in the morning shift from 9 am to 12 noon. Examinations of BA-III, BCom-III and BSc-III were conducted in second shift from 1 pm to 4...
Source : Times Of India |
Category : City | City : Kanpur

Girls outscore boys in BCom-III

Girls outshone boys in BCom final-year exams, the results of which were announced by Himachal Pradesh University (HPU) on Sunday. Only one boy has managed to find a place in the top-10 list. Overall result of BCom final-year was 97.09%. First top four positions have been clinched by girls.The result has relieved the students who were otherwise worried about their future due to delay in its declaration...
Source : Times Of India |
Category : City | City : Shimla

BCom III results out

Panjab University (PU) on Friday declared the result of B.Com-III. The result is available on the PU website results.puchd.ac.in. PU's controller of examinations Parvinder Singh said that 96.66% cleared the exam out of the 7,510 who appeared. Niharika Mehta of Sri Aurobindo College of Commerce & Management, Village Jhande, Ludhiana, has topped with 1,581 marks out of a total of 1,800. Jasleen Kaur...
Source : Times Of India |
Category : City | City : Chandigarh

Merck Serono announces results of the Phase III start trial investigating Tecemotide in non-small ce

page.Merck Serono announces results of the Phase III start trial investigating Tecemotide in non-small cell lung cancerMerck Serono announces results of the Phase III start trial investigating Tecemotide in non-small cell lung cancerhas published results from the Phase III trial of its investigational MUC1 antigen specificimmunotherapy tecemotide (also known as L-BLP25) in patients with unresectable,...
Source : Medicalnewstoday |
Category : Others

Secukinumab showed superior efficacy over etanercept in clearing skin, according to pivotal Novartis

Secukinumab showed superior efficacy over etanercept in clearing skin, according to pivotal Novartis Phase III psoriasis results presented at EADVSecukinumab showed superior efficacy over etanercept in clearing skin, according to pivotal Novartis Phase III psoriasis results presented at EADVNovartis has nnounced the results from the head-to-head Phase III FIXTURE study showing secukinumab (AIN457),...
Source : Medicalnewstoday |
Category : Others

Girls grab top 10 spots in PU's BCA-III results

Girls grabbed all the top 10 positions in BCA-III exams, according to the results declared by Panjab University (PU) on Monday. The result was declared on the PU website http://results.puchd.ac.in/PU's controller of examinations Parvinder Singh said 85.21% students had cleared the BCA-III exam. As many as 2,137 students had appeared for the examination and 1,821 have cleared it.Aanchal Gaba of Devki...
Source : Times Of India |
Category : City | City : Chandigarh

Veer Narmad South Gujarat University gears up to manage rush in BCom colleges

Anticipating high results of class XII (commerce), Veer Narmad South Gujarat University (VNSGU) is gearing up for admissions to Bachelor of Commerce (BCom), which has become the more sought-after course than BBA.The university is keeping alternative plan ready to accommodate maximum possible students in BCom colleges through centralized admission system.The general trend observed since 2012 is that...
Source : Times Of India |
Category : City | City : Surat

Forest Laboratories reports positive results from three Phase III trials of vilazodone for GAD treat

Forest Laboratories reports positive results from three Phase III trials of vilazodone for GAD treatmentForest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from three Phase III trials evaluating thedisorder (GAD). In two flexible-dose and one fixed-dose GAD trials, patients who received vilazodone demonstrated statistically significant improvement from baseline in the Hamilton...
Source : news-medical |
Category : Health

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTCEisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive(RR-DTC). Progression-free survival with lenvatinib was extended significantly compared to placebo>th Annual Meeting of the...
Source : news-medical |
Category : Health

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infect

first detailed results from AbbVie's (NYSE: ABBV) pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference onand safety of 12 weeks of treatment with AbbVie's investigational therapy with or withoutThe PEARL-III study met its primary and...
Source : news-medical |
Category : Health
Related search